ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
実験式(ヒル表記法):
C5H7NO3
CAS番号:
分子量:
129.11
NACRES:
NA.26
PubChem Substance ID:
UNSPSC Code:
12352209
EC Number:
202-700-3
MDL number:
Beilstein/REAXYS Number:
82132
製品名
L-ピログルタミン酸, BioXtra
product line
BioXtra
Quality Level
assay
≥97% (titration)
form
powder
technique(s)
cell culture | plant: suitable
impurities
≤0.0005% Phosphorus (P)
ign. residue
≤0.1%
color
white
mp
160-163 °C (lit.)
solubility
H2O: 1 M, clear, colorless
anion traces
chloride (Cl-): ≤0.05%, sulfate (SO42-): ≤0.05%
cation traces
Al: ≤0.0005%, Ca: ≤0.0005%, Cu: ≤0.0005%, Fe: ≤0.0005%, K: ≤0.005%, Mg: ≤0.0005%, NH4+: ≤0.05%, Na: ≤0.005%, Pb: ≤0.001%, Zn: ≤0.0005%
SMILES string
OC(=O)[C@@H]1CCC(=O)N1
InChI
1S/C5H7NO3/c7-4-2-1-3(6-4)5(8)9/h3H,1-2H2,(H,6,7)(H,8,9)/t3-/m0/s1
InChI key
ODHCTXKNWHHXJC-VKHMYHEASA-N
Still not finding the right product?
Explore all of our products under L-ピログルタミン酸
signalword
Danger
hcodes
Hazard Classifications
Aquatic Chronic 3 - Eye Dam. 1
保管分類
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Li-Hui Sun et al.
Chemical communications (Cambridge, England), 47(36), 10136-10138 (2011-08-11)
The chiral N-heterocyclic carbene bearing a proximal hydroxy group derived from L-pyroglutamic acid was found to be an efficient catalyst for the [3+2] annulation of enals and isatins to give the corresponding spirocyclic oxindolo-γ-butyrolactones in good yield with good diastereo-
Andrea Bednářová et al.
Comparative biochemistry and physiology. Part A, Molecular & integrative physiology, 164(1), 91-100 (2012-10-23)
Glucagon is conventionally regarded as a hormone, counter regulatory in function to insulin and plays a critical anti-hypoglycemic role by maintaining glucose homeostasis in both animals and humans. Glucagon performs this function by increasing hepatic glucose output to the blood
M H Creer et al.
Clinical chemistry, 35(4), 684-686 (1989-04-01)
Pyroglutamic acidemia, a rare metabolic disorder, usually appears in infancy. It is characterized by retardation, ataxia, hemolytic anemia, and chronic acidosis and is caused by a marked deficiency of glutathione synthetase (EC 6.3.2.3) activity. This disease is inherited as an
